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ABSTRACT 
Neuroinflammation is one of the key pathological events involved in the progression of brain damage caused 
by cerebral ischemia. Metabolism of arachidonic acid through cyclooxygenase (COX) enzymes is known to be 
actively involved in the neuroinflammatory events leading to neuronal death after ischemia. Two isoforms of 
COX, termed COX-1 and COX-2, have been identified. Unlike COX-1, COX-2 expression is dramatically 
induced by ischemia and appears to be an effector of tissue damage. This review article will focus specifically 
on the involvement of COX isozymes in brain ischemia. We will discuss issues related to the biochemistry and 
selective pharmacological inhibition of COX enzymes, and further refer to their expression in the brain under 
normal conditions and following excitotoxicity and ischemic cerebral injury. We will review present knowledge 
of the relative contribution of each COX isoform to the brain ischemic pathology, based on data from 
investigations utilizing selective COX-1/COX-2 inhibitors and genetic knockout mouse models. The 
mechanisms of neurotoxicity associated with increased COX activity after ischemia will also be examined. 
Finally, we will provide a critical evaluation of the therapeutic potential of COX inhibitors in cerebral ischemia 
and discuss new targets downstream of COX with potential neuroprotective ability.  
 
 
INTRODUCTION 
 
Cerebral ischemia is a leading cause of death and disability [1-4]. According to the World Health Organization 
(WHO), stroke is the second highest cause of mortality in the world and the third highest in developing 
countries. It is also a major cause of long-term disability worldwide [1;3;5-7], representing an important 
economic burden for society [8;9]. Very few therapeutic options are currently available [10], and there is an 
unmet need of neuroprotective agents to curtail the devastating cascade of pathological events triggered by 
the occlusion of a major brain vessel. Significant efforts have been devoted for decades to gain a better 
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understanding of the pathophysiological mechanisms leading to neuronal death following ischemia. The search 
for neuroprotective compounds and novel techniques for timely injury detection, such as magnetic resonance 
imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans, is actively 
progressing and has led to significant advances in our understanding of stroke pathogenesis. 
 
Among the damaging events following brain ischemia, excitotoxicity and alteration of intraneuronal Ca2+ 
homeostasis are considered early processes that propagate the cascade of harmful processes leading to brain 
infarction [11-13]. Data published over the past decade have provided insights into the evolution of injury, and 
have suggested a greater role for oxidative stress and inflammatory mediators [14-16].  
 
A wide body of evidence has recently accumulated supporting the notion that neuroinflammation plays a 
pivotal role in the progression of ischemic brain injury and pharmacological strategies aimed at reducing the 
inflammatory cascade following cerebral ischemia have proven to exert potent neuroprotection. Due to the 
concerted action of phospholipases, huge amounts of free arachidonic acid are released from membrane 
phospholipids after the ischemic event. The arachidonic acid metabolic pathway via cyclooxygenases is 
actively involved in neuroinflammation following the occlusion of cerebral blood vessels, and is a key 
component of the initiation and propagation of the inflammatory process after different types of brain injury 
including ischemia [17;18]. 
 
This review will focus specifically on the role of cyclooxygenase (COX) in ischemic brain injury. We first discuss 
aspects related to the biochemistry and pharmacological inhibition of COX, and further refer to the expression 
and role of each COX isozyme in excitotoxicity and ischemic cerebral injury. The mechanisms of toxicity of 
increased COX activity after brain ischemia are also examined. Finally, we provide a critical appraisal of the 
therapeutic potential of COX inhibitors in cerebral ischemia and discuss new potential targets downstream of 
COX with promising neuroprotective ability to ameliorate ischemic brain injury.  
 
 
BIOCHEMICAL ASPECTS OF CYCLOOXYGENASE 
 
Cyclooxygenase, more correctly termed prostaglandin-endoperoxide synthase, catalyzes the conversion of 
arachidonic acid (AA) into prostaglandin H2 (PGH2) via PGG2, a very short-lived endoperoxide intermediary 
[19-23]. PGH2 is the precursor of several other prostanoids, including prostaglandin E2 (PGE2), prostacyclin 
(PGI2), and thromboxanes (Figure 1). Although the more correct biochemical terminology for this enzyme is 
prostaglandin-endoperoxide synthase or prostaglandin G/H synthase (E.C. 1.14.99.1), its trivial name 
cyclooxygenase (COX) will be used throughout the present review article.  
 
Biochemical and structural studies of COX have identified two different catalytic sites: the cyclooxygenase and 
the peroxidase reactions [19;24]. Free AA is cyclized and bis-oxygenated to yield PGG2, an intermediary 
endoperoxide, in the cyclooxygenase site of the enzyme [19;24;25]. In a separate heme-containing peroxidase 
active site, a hydroperoxyl group in PGG2 is reduced to hydroxyl forming PGH2 [19;22]. It has been shown that 
free radical species are formed during the peroxidase reaction of COX (Figure 1), however, there is still debate 
on the identity of this free radical and the biological significance of its formation [22;23]. COX catalyzes the 
obliged reaction in the oxidative conversion of AA into different prostaglandins and thromboxanes, which are 
important in many physiological and pathological processes. It is important to mention that the production of 
PGH2 is self-limited due to suicide inactivation of COX [26-28]. The biological significance of this biochemical 
process is presently unknown.  
 
Once PGH2 is formed, several tissue-specific isomerases are responsible for the synthesis of different 
biologically active prostanoids (Figure 1) [29-34]. For example, prostaglandin E synthase (PGES) metabolizes 
PGH2 into PGE2 [29;31]. There are several other terminal synthases including prostacyclin synthase (PGIS), 
prostaglandin D2 synthase (PGD synthase), prostaglandin F2α synthase and thromboxane synthase (TXA2 
synthase) [34]. This biochemical pathway is further complicated by the occurrence of several isoforms of some 
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of the terminal synthases, and their differential expression in cell types during physiological and pathological 
conditions.  
 
The biological effects of each prostanoid depend on its binding to receptors coupled to specific signal 
transduction mechanisms modulating cell function (Figure 1). For example, four different receptors for PGE2 
have been identified, EP1 through EP4 [35-37]. Interestingly, these EP receptors mediate different and 
sometimes opposing responses: EP2 and EP4 lead to increase cAMP [38], while EP3 activation reduces 
cAMP [39], and EP1 increases intracellular Ca2+ [40;41]. Binding of PGD2 to its DP1 receptor leads to 
increased cAMP levels [42;43]. These few examples serve to exemplify the complexity of prostanoid signaling, 
an area of research that investigators have recently started to discover. This information will be needed to 
better understand both the physiological and pathological effects of prostanoids.  
 
Two different isoforms of COX, termed COX-1 and COX-2, have been cloned and extensively characterized 
[19;26;33;44]. COX-3, a putative isozyme of COX, was recently cloned, but it was found to be a splice variant 
of the transcript for COX-1 [45-47]. Great similarities between COX-1 and COX-2 have been observed [19]. 
They have an amino acid identity of approximately 60%, producing a 70 kDa protein that gets assembled 
within the lumen of the endoplasmic reticulum and nuclear envelope [19;33;44;48]. In terms of enzyme 
kinetics, both isoforms show very similar behavior [19;33;49]. Perhaps the most striking difference between 
COX-1 and COX-2 is their expression pattern. Data from different laboratories over several years have 
demonstrated the inducible nature of COX-2 as opposed to COX-1 [19;26;50-55]. The expression of COX-2 is 
upregulated by bacterial lipopolysaccharide (LPS), pro-inflammatory cytokines, growth factors, and tumor 
promoters, thereby distinguishing it from the primarily constitutive COX-1 isoform [52;54;56-62]. Due to this 
distinctive expression profile, COX-2 has been speculated to be the major isoform involved in inflammation and 
other pathologies.  
 
The slightly enlarged COX-2 active site relative to COX-1 is essential in the recognition of bulkier substrates by 
COX-2 [44]. For example, COX-2, but not COX-1, effectively oxidizes the endocannabinoids anandamide 
(arachidonyl ethanolamide) and 2-arachidonyl glycerol, yielding prostanoid-like oxidized endocannabinoids [63-
65]. The biological relevance of the COX-2-mediated metabolism of endocannabinoids is presently poorly 
understood.  
 
Outstanding reviews of COX structure and kinetics, prostanoid receptors and terminal synthases have recently 
been written [19;29;31;33;35;44;66;67], and thus, in this section we have only discussed the essential aspects 
of these topics needed to understand the role of COX in cerebral ischemia. 
 
 
PHARMACOLOGICAL INHIBITION OF CYCLOOXYGENASE  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most used drugs worldwide. In early 1971, Sir 
John R. Vane proposed that NSAIDs inhibit prostaglandin synthesis, and thus act as anti-inflammatory and 
ulcerogenic agents [68;69]. It has now become widely recognized that nearly all NSAIDs (e.g., aspirin, 
ibuprofen, indomethacin, naproxen) act by blocking the access of the AA substrate to the COX active site 
[70;71]. With the major exception of aspirin, which acetylates and permanently inhibits COX, the other NSAIDs 
inhibit COX by competing with AA for binding in the COX active site [70;71]. Nevertheless, there are significant 
differences among NSAIDs in whether they bind the COX active site in a time-dependent or independent way.  
 
Despite the similarities between COX-1 and COX-2 in terms of catalytic mechanisms and kinetics, there are 
two major structural differences that have important consequences from the pharmacological and biological 
viewpoint. First, COX-2 has a larger and more accommodating cyclooxygenase active site as compared with 
COX-1 [19;48]. This structural difference in the AA pocket size and shape has allowed the development of 
highly selective COX-2 inhibitors. Second, COX-1, as opposed to COX-2, exhibits negative allosterism at low 
AA concentrations. Thus, when both isoforms are expressed in the same cell, COX-2 competes more 
effectively for newly released AA [19].  
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The subtle structural differences between COX-1 and COX-2 have been exploited in order to develop selective 
inhibitors of each isoform [72;73]. This is a powerful pharmacological tool that, along with genetic knockout 
studies, has allowed the study of the specific physiological and pathological role of each COX isozyme.  
 
There are excellent review articles of the cyclooxygenase catalysis and inhibition by NSAIDs [19;44;66;74-76], 
which the reader is encouraged to reference the very detailed, and at times complex, mechanisms of inhibition 
and pharmacology of highly selective inhibitors of each COX isoform.  
 
BASAL CYCLOOXYGENASE EXPRESSION IN THE BRAIN 
 
Under normal conditions, COX-1 and COX-2 are expressed by specific neuronal populations [50]. COX-1 is 
widely expressed in neurons and microglia in several animal species [51;77-82], and its immunoreactivity is 
enriched in midbrain, pons and medulla [83]. COX-1 is intensely expressed in microglia in both rat [77] and 
human [51;84;85], and relative high levels are also found in hippocampal and cortical neurons in control human 
brain [51]. 
 
The brain is one of the few tissues that constitutively express COX-2 [86]. The immunoreactivity for COX-2 is 
primarily localized to neurons, and in the rat brain it prevails in the hippocampus with the densest staining in 
the dentate gyrus, piriform cortex, amygdala, and in layers II and III of the neocortex [81;83;87-89]. COX-2 
astrocytic immunoreactivity has been described in the white matter of the rat brain and spinal cord [90;91].  
 
Earlier studies have shown that synaptic stimuli induce neuronal COX-2 expression [87]. COX-2 expression 
colocalizes selectively with glutamatergic neurons [87;92], and seems to be coupled to excitatory neuronal 
activity [87;90;93-95]. It has been demonstrated that activation of the glutamatergic NMDA receptors results in 
increased neuronal COX-2 expression. Treatment with MK-801, a specific NMDA receptor antagonist, 
completely inhibited COX-2 induction following seizures [87].  
 
Only limited information is available about the normal function of COX-2 in the brain. Due to its localization in 
dendrites and dendritic spines, and its upregulation following synaptic activation, it has been suggested that 
COX-2 plays a role in synaptic signaling and memory consolidation [17;50;87;92;96]. In the hippocampal 
formation, COX-2 also has been implicated in learning and memory [87;96-102]. Furthermore, COX-2 plays an 
important role in mediating the changes in neocortical blood flow evoked by neural activity [103]. There is a 
modulatory role of arachidonic acid metabolites produced by COX-2 in the control of focal cerebral blood flow 
following local increases in neuronal activity, suggesting the involvement of COX-2 in cerebrovascular coupling 
[104]. This is a very important homeostatic mechanism matching the delivery of nutrients with the energy 
needs of the active brain [105-107].  
 
EXPRESSION OF CYCLOOXYGENASES FOLLOWING EXCITOTOXICITY OR CEREBRAL ISCHEMIC 
INJURY  
 
COX-2 is induced as an immediate early gene in a wide variety of cell types and in response to an ample 
variety of stimuli [44;50]. Since COX-2 expression is linked to synaptic activity, it is not surprising that its 
expression is dramatically increased following excitotoxic or ischemic injury.  
 
COX-2 expression following excitotoxicity  
 
Dramatic increases in COX-2 mRNA and protein levels occur following in vivo excitotoxic injury [93;94;108-
115]. Increased upregulation of COX-2 mRNA and protein has also been found in neuronal cultures exposed to 
excitotoxic insults in vitro [116;117]. On the contrary, COX-1 expression levels are not changed by excitotoxic 
damage [93;113]. The increased COX-2 expression following kainate excitotoxicity can be prevented by 
blockade of glutamate receptors [93], and by an antagonist of platelet-activating factor (PAF) receptor [95]. 
Substantial COX-2 overexpression was found in vulnerable neurons following kainic acid injection [94;111], 
and another study demonstrated localization of COX-2 in neurons undergoing apoptosis, as assessed using 
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immunohistochemistry and TUNEL assay 8 h after kainic acid injection [110]. These reports provide evidence 
suggesting that COX-2 activity is closely linked to excitotoxic neuronal death. However, not all cells 
overexpressing COX-2 are destined to die following kainic acid injection. For example, a dramatic and 
prolonged increase in COX-2 immunoreactivity is seen in the dentate gyrus granule neurons, but these cells 
are not vulnerable to kainic acid neurotoxicity [111].  
 
COX-2 expression after brain ischemia  
 
It has long been known that COX-2 expression is significantly and persistently increased following cerebral 
ischemia in different models. In this section, we will describe the most important observations of the effect of 
brain ischemia on COX-2 expression in both global and focal cerebral ischemia.  
 
Expression of COX-2 following global cerebral ischemia 
 
Global cerebral ischemia results from the transient cessation of blood flow to the brain, leading to a 
characteristic pattern of cell death in specific neuronal populations. The hippocampal CA1 region is considered 
the most susceptible to a global ischemic event [118-120]. Clinically, global brain ischemia occurs after 
cardiopulmonary bypass surgery or cardiac arrest with resuscitation, and is associated with problems with 
cognition and memory, sensorimotor deficits, seizures, and death [121].  
 
In a pioneer study, Ohtsuki and colleagues demonstrated induction of COX-2 mRNA in the gerbil hippocampus 
after transient global ischemia using Northern blotting and in situ hybridization [122]. Expression of COX-2 
mRNA was markedly induced at 3 h of reperfusion, but after 24 h, the signal became undetectable. In situ 
hybridization revealed that both the pyramidal cells of the CA1-4 regions and the granular cells of the dentate 
gyrus expressed COX-2 up to 16 h after ischemia [122]. Occlusion of both common carotid arteries in gerbils 
caused delayed neuronal death in CA1 and CA2 areas 7 days later, but CA3 and dentate granular cells were 
preserved, indicating that COX-2 expression did not correlate with the resultant outcome of neuronal death 
after the ischemic insult in all areas. Additionally, COX-2 mRNA was also induced in many cortical neurons that 
were resistant to 5-min global cerebral ischemia [122].  
 
In another study, both COX-2 mRNA and protein were substantially increased after ischemia in CA1 
hippocampal neurons before their death in a rat model of 20 min of global cerebral ischemia. Twenty-four 
hours after ischemia, there was a large increase in hippocampal PGE2 [123]. COX-2 protein induction peaked 
at 12-24 h after ischemia in several hippocampal regions, but in the CA1 neurons COX-2 was still seen at 3 
days following global ischemia [124]. Also in a global ischemia model, bilateral occlusion of both common 
carotid arteries in gerbils resulted in a biphasic and significant increase in hippocampal PGE2 concentrations (2 
and 24-48 h of recirculation). The late increase in PGE2 production preceded the onset of morphological 
changes in the CA1 subfield of the hippocampus [125]. Other studies have also confirmed previous 
observations of the significant increase in COX-2 expression following global ischemia [126-131].  
 
COX-2 expression in the brain subjected to focal cerebral ischemia 
 
Focal cerebral ischemia is produced when a major brain artery is blocked by a clot or bursts (brain 
hemorrhage). In the clinic, this type of injury is commonly referred to as ischemic or hemorrhagic stroke. In the 
industrialized countries, stroke is a leading cause of death and adult disability, representing a major public 
health problem [132]. 
  
A plethora of reports have shown that COX-2 expression is markedly upregulated following focal ischemia. 
Using a rat model of transient ischemic stroke induced by 1-h middle cerebral artery occlusion (MCAO) 
followed by reperfusion, Planas and co-workers demonstrated for the first time that COX-2 mRNA and protein 
are significantly induced in the ipsilateral cerebral cortex at 4 and 8 h after reperfusion, respectively [133]. 
These investigators also described colocalization of COX-2 and c-Fos immunoreactivities in superficial cortical 
layers within the ipsilateral hemisphere at 6 and 24 h following focal ischemia [111]. In permanent MCAO, a 
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significant increase in COX-2 mRNA was detected in the core and penumbra regions of the cerebral cortex 
between 4 and 24 h after the occlusion, and this was most marked at 4 h in the penumbral areas [134]. In this 
study, a correlation was shown between the extent of COX-2 mRNA induction in the cortex at 4 h and the 
severity of brain damage detected at 24 h post MCAO [134]. Administration of MK-801, an NMDA antagonist, 
significantly attenuated the induction of COX-2 after ischemia, suggesting the involvement of NMDA receptors 
in stroke-induced COX-2 expression [134].  
 
In an elegant study by the group of Dr. Costantino Iadecola [135], COX-2 mRNA was found to be upregulated 
in the ischemic hemisphere, but not contralaterally, beginning 6 h and persisting until 24 h after ischemia. They 
also found marked upregulation of COX-2 immunoreactivity at 12-24 h of reperfusion following 2 h of MCAO in 
the rat. Concentrations of PGE2 were elevated in the stroke side by about 300% at 24 h [135]. Similar results 
were obtained in another investigation, where 12 h following 90 min of ischemia, COX-2 mRNA was induced in 
all layers in the neocortex, perifocal striatum, piriform cortex, dentate gyrus, and CA1-4 pyramidal cell layers in 
the hippocampus, as assessed using in situ hybridization [136]. The induction was also seen at the protein 
level using immunohistochemistry and immunoblotting. Most of the COX-2 positive cells were neurons. 
However, endothelial cells around the blood vessels in the infarcted core were strongly stained using the COX-
2 antibody [136]. A similar increase in COX-2 in the vasculature was found in the piglet exposed to global 
ischemia or asphyxia, where marked immunofluorescence for COX-2 was observed in cerebral arteries and 
arterioles [137]. A more recent investigation found significant increase in COX-2 positive cells in the peri-infarct 
cortical area from 12 to 72 h after MCAO with reperfusion [138].   
 
Using rat models of permanent and temporary MCAO, Kinouchi et al [139] found that COX-2 mRNA was not 
significantly induced in the ischemic core (lateral striatum) but strongly induced in the penumbral areas, 
comprising the medial striatum, periphery of MCA cortex as well as adjacent cortex (cingulated cortex). In brain 
areas distant from the ischemic territory, COX-2 mRNA was only induced bilaterally in the hippocampus. The 
substantial induction of COX-2 mRNA persisted in all regions even at 24 h after both permanent and transient 
MCAO [139].  
 
In a more recent study, Yokota and colleagues [140] investigated the temporal and topographic profiles of 
COX-2 expression in permanent MCAO in rats. COX-2 mRNA increased significantly between 3 and 24 h of 
ischemia in the peri-infarct area compared to controls. In the ischemic core, significant increases in COX-2 
mRNA levels were seen following 6 h of ischemia, which remained elevated up to 24 h. COX-2 
immunoreactive neurons were found predominantly in the peri-infarct area, though elevations in the 
immunohistochemical staining of discrete neuronal populations were also observed in the ischemic core. 
Significant increases in PGE2 levels were found in the ischemic hemisphere following 24 h of ischemia. The 
upregulation of COX-2 mRNA in the peri-infarct area persisted for at least 24 h after ischemia, as did the 
production of COX-2 protein, which led to significant increases in prostacyclin (PGI2) as well as PGE2 levels 
following 24 h of ischemia. In the ischemic core, increases in COX-2 mRNA persisted during the 24 h of 
ischemia, though significant increases in COX-2 protein were not found [140]. They observed that the 
magnitude of COX-2 activity and prostaglandin production was determined by the degree and duration of 
cerebral blood flow (CBF) reduction [140;141]. 
 
Another important mechanism of COX-2 induction following ischemia, as observed in rodents and non-human 
primates, is spreading depression [136;142-144]. Spreading depression is a wave of reduced spontaneous 
electrical activity that spreads across the brain. Repetitive spreading depression waves originate from the 
ischemic core and progress outward toward the penumbra, and are thus called ischemic depolarizations. This 
phenomenon is thought to be associated with the progressive neuronal damage observed during brain 
ischemia, and influences the expression of many genes including COX-2.  
 
Unlike COX-2, COX-1 expression seems not to be affected by ischemic brain injury, as consistently reported 
by several groups using animal models of both global and focal cerebral ischemia [123;127;135;145;146]. 
However, Schwab and colleagues observed accumulation of COX-1-expressing microglial cells/macrophages 
in lesions of human focal ischemic stroke [85]. In support of this finding, a recent study has described 
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significant increase in the number of cells positive for COX-1 in the peri-infarct frontoparietal cortex in a rat 
model of ischemic stroke [138]. Based on these results, it has been suggested that while the global levels of 
COX-1 may not increase following brain ischemia, it is possible that in those regions where there is 
proliferation and migration of microglia, there is indeed an increase in the expression of COX-1 [17;147].  
 
As discussed earlier in this review, COX-2 expression is substantially increased following brain ischemia in 
rodents. However, these observations are not only restricted to experimental models. It is important to highlight 
that several reports have also described significant upregulation of COX-2 protein in post-mortem tissue 
obtained from humans with cerebral ischemia. In globally infarcted human brain, COX-2 protein was present in 
both neuronal and glial cells throughout the brain in accord with infarct topography and duration [148]. These 
authors suggested that the early induction of COX-2 may be involved in tissue injury, while the delayed 
induction in areas remote from the infarct may promote tissue scaring and remodeling [148]. In the acute 
stages of cerebral ischemic infarction, COX-2 protein was present in infiltrating neutrophils, vascular cells and 
neurons located at the border of the infarct, raising the possibility that COX-2 is involved in ischemic injury in 
the human brain [149]. In individuals who died two or more weeks after resuscitation (global brain ischemia), 
high expression of COX-2 protein was detected in macrophages and leukocytes at the center of the necrotic 
area. Reactive astrocytes and blood vessels were also COX-2 immunopositive [150]. In another study, 
Tomimoto and co-workers found strong immunoreactivity for COX-2 in microglia in the brains of patients who 
died from chronic cerebral ischemia such as Binswanger’s disease [151]. Moreover, overexpression of COX-2 
has also been shown in the ischemic neonatal human brain (neonates delivered after severe birth asphyxia) 
[152].  
 
A wide body of evidence supports the notion that COX-2 induction could be responsible for a major component 
of tissue damage occurring in ischemia and represents and important target for treatment. However, it must be 
emphasized that COX-2 expression by itself does not lead to neuronal death since a variety of healthy 
neuronal populations throughout the CNS express COX-2 mRNA and protein under normal conditions [83;87] 
and COX-2 expression can be experimentally induced without causing death of these neurons [153]. 
 
In the study of Planas et al. [153], they found the same level of COX-2 induction in response to both mild 
ischemia (10 min of MCAO), which does not cause inflammation or cell death, and 1 h of stroke which leads to 
brain infarct. These data suggest that COX-2 would only mediate neuronal injury in the context of an 
inflammatory response. In support of this study, Yokota and colleagues found that in a primate model of 
permanent carotid artery embolization, COX-2 expression persisted even 24 h after ischemia in regions of the 
ipsilateral parietal cortex representing potentially viable tissue where cerebral glucose metabolic rate was 
preserved. This supports the notion that COX-2 induction is not always associated with cell death.  
 
 
 
ROLE OF CYCLOOXYGENASES IN BRAIN INJURY FOLLOWING ISCHEMIA 
 
The relative contribution of each COX isoform to brain damage induced by ischemia has been extensively 
studied using pharmacological and genetic approaches. The availability of highly selective inhibitors of either 
COX-1 or COX-2 is a very powerful pharmacological tool to study the role that these specific isozymes play in 
the ischemic cascade. In addition, mice lacking each of these enzymes have been described, and extensively 
characterized in models of inflammation, cancer, pain, excitotoxicity, and cerebral ischemia.  
Pharmacological studies using COX inhibitors in models of brain ischemia 
Numerous studies published several years ago showed that inhibition of COX using non-selective inhibitors 
protected against neuronal injury after ischemia in some animal models. Pre-treatment with indomethacin, an 
inhibitor of COX-1 and COX-2, has been shown to reduce infarct size and completely abolished the production 
of PGD2 following focal brain ischemia [154;155]. It also diminished glutamate release from the ischemic 
cerebral cortex in a rat model of four-vessel occlusion, which results in global brain ischemia [156]. 
Indomethacin also ameliorated neuronal death in the hippocampal CA1 sector following 5 min of forebrain 
ischemia in gerbils [157;158], and reduced the number of TUNEL-positive CA1 pyramidal neurons in the same 
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ischemia model [159-161]. However, using a similar dose, but a longer time of occlusion (10 min), 
indomethacin failed to reduce CA1 neuronal death [162]. This is in contrast to other reports in which edema 
formation is significantly reduced in the ischemic gerbil brain after treatment with indomethacin [163;164]. 
Piroxicam, a COX inhibitor widely used in the clinic, was also found to be very effective in reducing PGE2 
formation in the hippocampus and delayed neuronal death after global ischemia in both rats and gerbils 
[123;165]. Ischemic loss of CA1 neurons, assessed 7 days after common carotid artery occlusion in gerbils, is 
prevented by repeated treatment for 3 days with flurbiprofen [165].  
 
Ibuprofen, another non-selective COX inhibitor, ameliorated delayed CA1 neuronal death in a model of global 
ischemia in rats [166;167], and reduced infarct size in temporary focal ischemia [168;169]. Interestingly, 
ibuprofen was not effective in reducing focal ischemic damage in a permanent MCAO model, even when 
administered at the same dose at which it was effective in transient MCAO [168]. Similarly, a very recent study 
has found that aspirin, given in repeated doses at a relatively high dose of 40 mg/kg, reduced infarct size in a 
transient [170;171], but not in a permanent, MCAO model in rats [171]. Of interest is the finding that aspirin 
reduces infarction and improves neurological recovery in temporary focal ischemia even when the first 
treatment is started up to 6 h after the onset of MCAO [172]. Moreover, KBT-3022, another non-selective COX 
inhibitor, was as effective as indomethacin in reducing CA1 neuronal cell death in a global ischemia model in 
gerbils [173]. In the same study, aspirin failed to reduce ischemic brain injury even at doses as high as 300 
mg/kg [173]. Furthermore, the COX inhibitor tenoxicam significantly reduced hippocampal and striatal damage 
in rats subjected to bilateral common carotid artery occlusion for 45 min followed by 24 h of reperfusion [174]. It 
was also found that tenoxicam completely prevented ischemia-induced increase in myeloperoxidase activity 
(an index of infiltration of leukocytes) [174].  
 
The COX-2 selective inhibitors NS-398 and valdecoxib and the non-selective inhibitor ketorolac have potent 
effects on cell death in cortical primary rat neuronal cultures subjected to hypoxia. These compounds reduced 
cell death by 70-95% at maximally effective doses [175].  
 
It should be noted that treatment with non-selective COX inhibitors has not always resulted in neuroprotection. 
For example, indomethacin failed to increase the survival of CA1 hippocampal neurons in rats subjected to 
global ischemia [176], which is in contrast to what was found in gerbils [157]. Ibuprofen significantly increased 
the size of infarct in a model of permanent MCAO [168]. Furthermore, a very recent study showed that two 
COX inhibitors, indomethacin and NS-398, increased the proportion of animals displaying neuronal damage in 
a rat model of permanent cerebral hypoperfusion [177]. Findings from another report indicate that chronic 
inhibition of COX-2 with NS-398 only provided limited functional improvement following motor cortex stroke 
[178].  
 
The chemical and pharmaceutical development of selective COX-2 inhibitors has fueled several investigations 
of their effects in models of cerebral ischemia. A wide body of evidence indicates that COX-2 inhibition confers 
neuroprotection in both global and focal ischemia. The protection is long-lasting and is also observed in rat and 
mouse models of permanent MCAO. More importantly, reduction in cell death correlated with improved 
recovery of the neurological function in ischemic animals treated with COX-2 inhibitors.  
 
The COX-2 selective inhibitor NS-398 (20 mg/kg) reduced cortical, but not subcortical infarct volume at 3 days 
when administered starting 6 h following 2 h of MCAO in the rat. This was accompanied by a significant 
reduction in postischemic increase of PGE2 production in the cerebral cortex [135]. Using the same rat model, 
Hara and co-workers found that the ischemic hemisphere had a significantly lower PGE2 concentration 
compared with the contralateral hemisphere in the NS-398-treated group [179]. However, they observed no 
effect of NS-398 (10 mg/kg) on infarct size when rats were sacrificed after only 4 h of reperfusion. The 
discrepancy between these two reports [135;179] may be due to different time points at which the infarct 
volume was investigated. In addition, after 4 h of reperfusion, only the core of the lesion (mainly striatal areas) 
is overtly infarcted, and COX-2 does not seem to play an important role in the early death of the ischemic core 
[135], but rather is actively involved in the progression of the cortical injury in this rat model of focal ischemia 
[135;180;181]. In mice subjected to distal permanent MCAO, delayed administration of NS-398 (starting 18 h 
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after the onset of stroke) was effective in diminishing infarct size and neurological deficits [182]. Surprisingly, 
there is a report indicating that NS-398 and nimesulide aggravate neuronal death by enhancing the increases 
in extracellular glutamate and intracellular Ca2+ levels following oxygen-glucose deprivation in rat primary 
cortical neurons [183]. The mechanism(s) underlying this toxic effect of these COX-2 inhibitors is presently not 
known, and is in sharp contrast with data obtained in in vivo models of cerebral ischemia.  
 
Nimesulide is a selective COX-2 inhibitor with the ability to rapidly and readily cross the blood-brain barrier 
[184;185]. It is structurally very similar to NS-398 and belongs to the class of acidic sulfonamides [44]. The 
neuroprotective efficacy of nimesulide has been extensively studied and overwhelming evidence indicates that 
it is a very promising neuroprotectant. Bilateral ligation of the common carotid arteries in the rat induces 
chronic cerebral hypoperfusion leading to white matter injury [186]. Treatment with nimesulide significantly 
attenuated white matter injury and microglial activation in this animal model [186]. Nimesulide was also very 
effective in reducing delayed neuronal death of hippocampal CA1 neurons following transient global ischemia 
in both gerbils [187] and mice [127]. Of interest is the finding that nimesulide rescued CA1 pyramidal neurons 
from ischemic death even when treatment was delayed until 24 h after ischemia, and the neuroprotective effect 
of nimesulide is still evident 30 days after the ischemic episode [187]. This suggests that COX-2 inhibitors 
confer long-lasting neuroprotection. Attenuation of oxidative stress seems to contribute to nimesulide’s 
protective ability in global brain ischemia [188;189].  
 
In focal ischemic brain injury, nimesulide significantly reduces infarct volume. It produced a more significant 
reduction in cortical than in striatal infarct after 1 h MCAO followed by 3 days of reperfusion [180]. Substantial 
protection by nimesulide was observed even when the first dose was given 24 hours after ischemic stroke, 
indicating a wide therapeutic window for neuroprotection with this COX-2 inhibitor [180]. Importantly, delayed 
treatment with nimesulide also improved neurological function as demonstrated by a better performance of 
treated rats in the rotarod test and lesser neurological deficit scores compared with vehicle-treated animals 
[180]. Stroke-induced elevation in PGE2 levels in the cerebral cortex was completely prevented by nimesulide 
administration [180]. It has also been shown that nimesulide attenuates ischemic brain injury resulting from 
permanent MCAO in terms of reduction in infarct size and improvement of the neurological function [190]. In a 
very recent report, inhibition of COX-2 with nimesulide was found to effectively limit the blood-brain barrier 
breakdown, leukocyte infiltration, and vasogenic edema induced by focal cerebral ischemia [181]. Interestingly, 
in the same study, administration of the selective COX-1 inhibitor valeryl salicylate had no effect on the 
ischemic outcome, suggesting that COX-1 seems not to play an important role in the evolution of focal 
ischemic damage [181]. Using an embolic stroke model in rats, Wang et al. [191] confirmed the 
neuroprotective ability of nimesulide. It was found that administration of clinically relevant doses of nimesulide 
decreased neurological deficits, infarct volume, and brain edema. Hemorrhagic transformation was reduced by 
64% with treatment of 12 mg/kg nimesulide. They also showed that the number of cells expressing matrix 
metalloproteinase (MMP)-9 and MMP-2 increased in the ischemic animals treated with vehicle, and 
significantly decreased in nimesulide-treated animals. This finding is of great relevance since MMPs have been 
shown to be actively involved in the detrimental pathological cascade resulting in ischemic injury, mainly due to 
their ability to disrupt most of the components of the blood-brain barrier [192-196]. The reduction in gelatinase 
content (MMP-2 and MMP-9) after ischemia in animals treated with nimesulide [191] helps to explain the 
protective effect of this COX-2 inhibitor against BBB breakdown and leukocyte infiltration, as shown in a 
previous study [181]. 
Advances in medicinal chemistry and considerable input from several pharmaceutical companies allowed the 
discovery of several highly selective COX-2 inhibitors. These agents have been tested in models of cerebral 
ischemia. In a seminal investigation by Nakayama and colleagues [123], it was convincingly demonstrated that 
COX-2 plays a role of paramount importance in the delayed neuronal death of CA1 hippocampal neurons 
following global ischemia. In this study, SC58125 was effective in preventing ischemia-induced elevation of 
hippocampal PGE2 and delayed neuronal cell death [123]. Also in global ischemia, another highly selective 
COX-2 inhibitor, DFU, protected hippocampal neurons against transient forebrain ischemia even when 
administered several hours after the onset of reperfusion. DFU also reduced the increase in spontaneous 
locomotor activity seen in ischemic gerbils 7 days after 5 min of bilateral common carotid occlusion [197].  
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The relative contribution of each COX isoform to neurodegeneration and oxidative damage induced by global 
ischemia has been investigated using highly selective inhibitors of these enzymes [125]. It is of importance to 
emphasize that this study showed that either the selective inhibition of COX-2 with rofecoxib (Vioxx) or COX-1 
inhibition with valeryl salicylate rescued CA1 hippocampal neurons from delayed ischemic death. It was also 
found in this investigation that inhibition of either COX-1 or COX-2 significantly limited oxidative damage to the 
hippocampus [125]. These data indicate that COX-1 seems also to be important in the neurodegenerative 
events triggered by global ischemia, and provided the first evidence indicating that both COX isoforms are 
involved in the progression of neuronal damage following global ischemia. These results are somehow 
unexpected since COX-1 is not induced after ischemia [123;135]. Nevertheless, the COX-1 inhibitor was as 
effective as the COX-2 inhibitor rofecoxib in attenuating delayed neuronal death after global ischemia [125]. 
This is in sharp contrast to findings from another study in which inhibition of COX-1 failed to modify brain injury 
induced by focal ischemia [181].  
 
Pharmacological inhibition of COX-2 with SC58236 dose-dependently prevented PGD2 increase and caused a 
significant reduction in the damaged area in a rat model of photothrombotic stroke [198]. More recently, Kelsen 
and co-workers found that administration of parecoxib, the water-soluble prodrug of valdecoxib (highly 
selective COX-2 inhibitor), produced a significant reduction in infarct volume when assessed 7 days after 
temporary MCAO in the spontaneously hypertensive rat [146]. Interestingly, they found a divided treatment 
response with responder and non-responder animals [146]. The reason(s) for this phenomenon was not 
clarified in the paper.  
 
It should be noted that, at least in focal cerebral ischemia, the neuroprotective efficacy of COX-2 inhibitors is 
lost in mice lacking the inducible nitric oxide synthase (iNOS) gene [199]. This is a very interesting finding, and 
suggests that iNOS-derived nitric oxide production is required for COX-2 neurotoxicity in the context of cerebral 
ischemia [199]. In the focal ischemic stroke, COX-2 upregulation occurs with a time course very similar to that 
of iNOS [135;200]. Pharmacological inhibition or genetic ablation of iNOS significantly reduced postischemic 
increase in PGE2 in the rat brain, indicating that nitric oxide formed by the action of iNOS drives COX-2 
catalytic activity [201;202].   
 
Studies in COX-1 and COX-2 knockout mice subjected to brain ischemia 
 
Investigations on COX-1 and COX-2 null mice have provided significant information on the roles that these 
isozymes play in ischemic brain injury. In line with the pharmacological studies, it was found that COX-2 
knockout mice are less susceptible to MCAO, displaying a significant reduction in infarct size and PGE2 
accumulation in the ischemic cerebral cortex [145]. Similarly, COX-2-deficient mice showed a substantial 
reduction in hippocampal neuronal death after global ischemia in comparison with wild-type mice [127]. 
Conversely, neuronal overexpression of the human COX-2 gene in a transgenic mouse model exacerbates 
focal ischemic injury, as reported in an interesting study by Doré and colleagues [203]. Overexpression of 
COX-2 in transgenic mice resulted in a dramatic increase in infarct volume and post-ischemic production of 
PGE2 and PGF2α when compared with non-transgenic controls [203]. Furthermore, global ischemia resulted in 
significantly higher neuronal damage in the CA1 region of the hippocampus of transgenic mice with neuronal 
overexpression of COX-2 than in wild-type controls [204], indicating a deleterious role of COX-2 in ischemic 
neuronal damage. In addition, primary cortical neurons prepared from COX-2 deficient mice are more resistant 
to hypoxia than control cells [175].  
 
On the other hand, genetic disruption of COX-1 decreases resting cerebral blood flow [205] and results in 
enhancement of infarct size and neurological deficits following distal MCAO [206]. However, these detrimental 
effects of COX-1 knockout were not confirmed in a model of permanent endovascular occlusion of the middle 
cerebral artery, where no difference on stroke outcome was observed between COX-1 null mice and wild-type 
controls [207]. In support of this, another report showed no modification in infarct size between COX-1 
knockout and wild-type mice in a photothrombotic model of stroke [208]. Moreover, selective inhibition of COX-
1 was proven not to modify infarct size or neurological deficits in rats subjected to transient ischemic stroke 
[181]. On the contrary, Lin et al. [209] found a neuroprotective effect against focal ischemic injury after infusion 
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into the rat lateral ventricle of recombinant adenoviruses containing either COX-1 or COX-1 plus prostacyclin 
synthase (PGIS). These apparently contradictory studies suggest that more work should be done in order to 
clarify the role of COX-1 in cerebral ischemia.  
 
 
CYCLOOXYGENASE INHIBITION IN MODELS OF EXCITOTOXIC BRAIN INJURY 
 
Excitotoxicity and the resulting alteration of intraneuronal Ca2+ homeostasis are among the most important 
pathophysiological events following brain ischemia [11]. These early processes propagate the cascade of 
harmful events leading to cerebral infarction [12;13]. As mentioned before, COX-2 expression is increased 
after activation of ionotropic glutamate receptors, and it has been proposed that enhanced COX-2 activity 
mediates, at least in part, the neurotoxicity associated to over-excitation of glutamate receptors after ischemia. 
However, there are conflicting data in this regard, as described below.  
 
It has been demonstrated that COX-2 deficient mice displayed a reduced damage following intracerebral 
injection of NMDA [145;210], and administration of selective COX-2 inhibitors significantly attenuated this type 
of injury [145;210;211]. It has also been shown that the non-selective COX inhibitor, naproxen, significantly 
reduced brain edema and neuronal loss in a mouse model of intrahippocampal injection of NMDA [212]. 
Neuroprotective efficacy was still evident when naproxen administration was started 6 h after NMDA 
microinjection [212]. Furthermore, COX-2 selective blockade, but not COX-1 inhibition, has been demonstrated 
to effectively reduce brain damage caused by direct injection of the excitotoxins quinolinic acid [213] and 
quisqualic acid [214;215].   
 
Using mixed mouse cortical cultures containing both neurons and astrocytes, Hewett and co-workers [116] 
found that flurbiprofen, a nonselective COX-1/COX-2 inhibitor, and the COX-2 selective inhibitor NS-398 
prevented NMDA-induced production of prostaglandins and attenuated neuronal death. COX-1 inhibition with 
valeryl salicylate had no effect on neuronal death. This study also showed that the newly synthesized COX-2 
protein is the one that contributes to NMDA neurotoxicity. This conclusion was based on two experimental 
findings: 1) inhibition of total COX activity with aspirin before NMDA exposure failed to prevent cell death; and 
2) treatment with flurbiprofen after NMDA significantly attenuated neuronal death [116].  
 
Two structurally distinct selective COX-2 inhibitors (NS-398 and APHS) were found to confer neuroprotection 
against NMDA-mediated excitotoxicity in an in vitro neuronal culture. The neuroprotective effect of APHS was 
reversed by the administration of PGE2 or by a concentration-dependent treatment with 17-phenyl-trinor-PGE2, 
which is a relatively specific agonist of EP1 and EP3 prostanoid receptors [216].  
 
Interestingly, COX inhibitors do not protect against the neurotoxicity induced by the excitotoxin kainate, 
suggesting that the protection conferred by COX-2 inhibition is specific for NMDA [116]. In support of these 
data, another study performed in cerebellar granule neurons demonstrated that the highly selective COX-2 
inhibitor, DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl) phenyl-2(5H)-furanone, completely 
protected cultured neurons against glutamate-mediated toxicity, and resulted in a significant attenuation of 
apoptotic cell death induced by an excitotoxic concentration of NMDA. In contrast, no protection from kainate-
mediated neurotoxicity was observed [117]. Nevertheless, there is a report indicating that in primary cortical 
neurons, both indomethacin (non-selective inhibitor) and aspirin (COX-1 preferential inhibitor) reduced kainate-
induced neuronal cell death, while NS-398 (COX-2 selective) had no effect. However, in primary hippocampal 
neurons, COX-2 inhibition prevented both kainate-induced cell death and PGE2 synthesis [217].  
 
Administration of COX inhibitors to animals injected systemically with kainate has produced mixed results. Pre-
treatment of mice with the COX-2 selective inhibitor NS-398 increases hippocampal neuronal cell death and 
enhances mortality in the kainic acid model [218]. A very recent study also showed that COX-2-deficient mice, 
but not COX-1 knockout mice, exhibit an increased sensitivity to kainate-induced seizures and are more 
susceptible than COX-2 wild-type animals to excitotoxic neuronal damage [219]. They also found that chronic 
administration of celecoxib (COX-2 selective inhibitor) recapitulated the increased susceptibility to kainate 
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neurotoxicity observed in COX-2-null mice [219]. These findings are not in line with data from another 
investigation demonstrating that transgenic mice with neuronal overexpression of human COX-2 showed a 
dramatic increase in neuronal damage following kainate injection, and glutamate excitotoxicity is potentiated in 
primary cortico-hippocampal neurons derived from these transgenic mice [220].  
 
These apparent discrepancies in data from in vivo studies using the kainate model might be the result of 
several factors, including the timing of administration of the COX-2 inhibitor. Treatment with COX-2 inhibitors 
before kainate aggravates neuronal death and seizure severity [218;221], but post-treatment with COX-2 
inhibitors corrected learning and memory deficits and prevented excitotoxic neuronal death in the hippocampus 
[222-225]. These findings suggest that inhibition of newly synthesized COX-2 induced by excitotoxins may 
confer protection, but blockade of basal COX-2 activity may be detrimental following kainate excitotoxicity. 
 
 
MECHANISMS OF TOXICITY OF ENHANCED COX ACTIVITY FOLLOWING CEREBRAL ISCHEMIA 
 
There are several factors responsible for the cytotoxicity of COX-2 in the setting of cerebral ischemia, which 
result in neuronal injury. The increased production of free radicals and PGE2 are among the most recognized 
mechanisms of toxicity linked to increased COX-2 activity. However, there are also two other processes, 
modulated by COX-2, which could potentially lead to neuronal death: 1) promotion of cell cycle activity by 
increasing cyclin D1 expression, and 2) metabolism of endocannabinoids (Figure 2). 
 
Cerebral ischemia results in a substantial increase in the availability of arachidonic acid, the substrate for the 
COX enzymatic pathway. A wide body of experimental evidence supports the theory that COX catalytic activity 
in linked to the production of free radicals. Oxidative stress is considered to be one of the major determinants 
of ischemic neuronal death [226-228]. Detailed biochemical investigations have demonstrated that free radicals 
are indeed produced by the peroxidase step of the COX reaction in which PGG2 is converted to PGH2 [23;229-
234]. Although it has become customary to consider reactive oxygen species (ROS), and specifically 
superoxide anion (O2·-), to be the primary radical produced by COX activity during inflammation, there is no 
direct evidence for this notion. On the contrary, the two major types of radicals so far known to be involved in 
COX activity are tyrosyl radicals on proteins [23] and carbon-centered radicals on the substrate arachidonic 
acid [232]. Due to the characteristically short half-life of free radicals, and the technical difficulties associated 
with their direct measurement in biological systems, there is still debate on the chemical nature of the free 
radical(s) involved in COX-2-mediated oxidative stress during inflammation and cerebral ischemia. However, 
there is an overwhelming line of evidence indicating that enhanced COX activity following cerebral ischemia 
and excitotoxicity is associated with oxidative damage.     
 
Pharmacological inhibition of COX-2 with either nimesulide or rofecoxib resulted in a significant reduction in 
measures of oxidative injury in the hippocampus following global cerebral ischemia in gerbils. These COX-2 
inhibitors prevented ischemia-induced glutathione depletion and the increase in lipid peroxidation, as assessed 
by the levels of lipid hydroperoxides, malondialdehyde (MDA) and 4-hydroxy-alkenals [125;188]. In a rat model 
of global forebrain ischemia, nimesulide treatment reduced lipid peroxidation and prevented the depletion of 
reduced glutathione following reperfusion [189]. Similarly, indomethacin treatment significantly reduced 8-
hydroxy-deoxyguanosine (8-OH-dG), a highly sensitive marker of DNA oxidation, in the ischemic hippocampus 
[161]. In in vivo models of excitotoxicity, COX-2 has been also demonstrated to be a significant source of free 
radicals. Treatment with nimesulide significantly reduced oxidative injury in the rat hippocampus after systemic 
kainate injection [235]. A microdialysis study in the hippocampus of freely moving rats showed that the COX 
inhibitors flurbiprofen and indomethacin, or the COX-2 selective inhibitor NS-398 effectively reduced 8-epi-
PGF2α (15-F2t-IsoP), a reliable marker of free radical-mediated lipid peroxidation [236], following infusion of 
NMDA [237]. Interestingly, using the same rat model of excitotoxicity, inhibition of COX-1 with SC-560 
significantly attenuated the increase in hippocampal 8-epi-PGF2α levels induced by NMDA [238]. In support of 
this study, it has been reported that the COX-1 inhibitor valeryl salicylate reduced measures of oxidative stress 
in the gerbil hippocampus following temporary global ischemia [125]. This suggests that COX-1 may also 
contribute to oxidative injury following excitotoxicity and brain ischemia.  
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Data from in vitro studies indicate that enhanced COX activity results in oxidative stress in neuronal and 
microglial cells exposed to inflammatory conditions. Inhibition of COX-2 activity with SC-58125, COX-1 
inhibition with aspirin, or blockade of COX-1 and COX-2 with indomethacin significantly reduced the formation 
of 8-epi-PGF2α, a biomarker of lipid peroxidation, in human neuronal cells exposed to IL-1β [239]. Furthermore, 
treatment with indomethacin prevented glutathione depletion in a rat model of neuroinflammation induced by 
intracerebral injection of TNF-α [240].  
 
Microglial activation is actively involved in brain ischemia and neurodegeneration [55;241-245]. In LPS-
activated microglia, selective inhibition of either COX-2 or COX-1 activity significantly attenuated the formation 
of free radicals and the ensuing lipid peroxidation [53;246]. In mouse microglial cells subjected to 
anoxia/reoxygenation, inhibition of COX with indomethacin attenuated the production of free radicals and 
diminished the oxidative damage to lipids and proteins [247]. Interestingly, the highly COX-1 selective inhibitors 
SC-560 and valeryl salicylate completely prevented PGE2 production and lipid peroxidation in LPS-activated 
microglial cells [246;248], despite the fact that COX-1 is not induced by LPS in these cells. Also in vivo, COX-1 
inhibition attenuated LPS-induced oxidative stress and brain injury [249]. These recent findings suggest that 
the contribution of COX-1 to neurotoxicity following ischemic and inflammatory injury should not be ignored.  
 
Results from all the above-mentioned investigations convincingly indicate that COX activity is a significant 
source of free radicals during cerebral ischemia and excitotoxicity. However, a couple of reports from Dr. 
Iadecola’s group have challenged this idea. They found that COX-2 selective inhibition with NS-398 or COX-2 
genetic ablation diminished lesion volume, but did not reduce ROS formation in mice with NMDA-induced 
neocortical lesions. The protection conferred by NS-398 is counteracted by a stable analog of PGE2 [210]. 
Authors concluded that COX-2-derived prostanoids, rather than ROS, mediate the COX-2-dependent 
component of the damage mediated by the activation of NMDA receptors. In a similar study, but using a mouse 
MCAO model of focal ischemia, they showed that NS-398 attenuated the production of PGE2 and reduced 
infarct size, but did not affect ROS production. Similarly, ROS formation was not reduced in COX-2 knockout 
mice [250]. Data from both of these studies should be carefully interpreted. They used hydroethidine 
fluoromicrography to assess ROS formation. This method only detects the production of ROS, mainly O2·- 
[251-253]. Since emerging evidence indicate that O2·- is not the major radical formed by COX activity [23;232], 
the apparent discrepancies between these two reports [210;250] and results from other studies 
[125;161;188;237;238;249] could be explained by the different methodological approach utilized. Unlike 
Iadecola’s studies, other investigations have measured markers of oxidative stress (e.g., glutathione levels, 
MDA, lipid hydroperoxides, isoprostanes, protein and DNA oxidation) instead of direct ROS detection. As 
mentioned before, the identity of the radical species formed during COX catalysis has not been established. 
Irrespective of the chemical nature of the radical formed by COX, by measuring biomarkers of oxidative 
damage, several studies have convincingly shown that increased COX activity contributes to oxidative stress 
following ischemic and excitotoxic brain injury [125;161;188;237;238]. It has also been demonstrated that 
oxidative stress directly induced neuronal COX-2 transcription [254-256]. This could lead to a vicious cycle 
associated with neurotoxicity.     
  
Production of pro-inflammatory prostanoids, and more specifically PGE2, is another pivotal mechanism of 
neurotoxicity associated to increased COX activity after ischemia and excitotoxicity. Work by Manabe and co-
workers indicated that PGE2, but not PGF2α, mediates, at least in part, the neurotoxicity of COX-2 following 
microinjection of NMDA into the neocortex in mice [210]. In addition, recent data indicate that the activation of 
the PGE2 receptor EP1 underlie the neurotoxicity of COX-2. Pharmacological blockade or gene inactivation of 
EP1 receptors reduce neuronal damage induced by focal cerebral ischemia, excitotoxicity, and oxygen-glucose 
deprivation [257;258]. More recently, it has been shown that activation of the EP3 receptor exacerbates 
ischemic and excitotoxic brain injury in vivo [259].  
 
It has long been described that PGE2 may mediate both detrimental and beneficial effects on neuronal survival. 
Addition of PGE2 induced apoptotic cell death in rat cortical and hippocampal neurons [260-263], and PGE2 
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has been shown to increase glutamate release from astrocytes, which may potentiate excitotoxicity in the 
setting of cerebral ischemia [264]. However, it should be emphasized that numerous reports describe 
neuroprotective effects of PGE2 against excitotoxicity and cerebral ischemia [265-267]. The type of PGE2 
receptor activated seems to determine whether PGE2 exerts neuroprotection or neurotoxicity. Activation of 
either EP2 or EP4 results in neuroprotection against NMDA-mediated excitotoxicity [267-269], ischemia in vivo 
[267;270], and oxygen-glucose deprivation in vitro [267].  Binding of PGE2 to EP1 or EP3 results in 
neurotoxicity in the setting of excitotoxic or ischemic events, as emerging evidence indicates [257-259;271].  
 
The notion that PGE2 is an important protagonist in the neuroinflammatory cascade which follows cerebral 
ischemia is further supported by a very recent investigation demonstrating that mice deficient in microsomal 
PGE2 synthase-1 (mPGES-1), the most important isoform responsible for PGE2 synthesis during 
neuroinflammation [272;273], displayed a significant reduction in ischemic brain injury as compared to wild-
type animals [274]. In mPGES-1 null mice, in which the cortical postischemic production of PGE2 was 
completely absent, the infarction, edema, apoptotic cell death, and caspase-3 activation after ischemia were all 
reduced compared with those in wild-type mice [274]. Of great interest was the finding that the improved 
outcome observed in mPGES-1 knockouts after focal ischemia were reversed to almost the same severity as 
wild-type animals by intracerebroventricular microinjection of PGE2 into knockout mice [274].    
 
Another mechanism by which COX-2 mediates the neurotoxic effect in ischemic brain injury is through 
promotion of the cell cycle activity [275;276]. Post-mitotic neurons are devoid of the capacity to divide or 
replicate, and are believed to be in the state of extended G0 phase. There are several stimuli which promote 
these post-mitotic neurons to divide. However, the lack of complete cell cycle machinery is lethal and such 
neurons undergo apoptotic cell death [275;277]. G1 cyclins are involved in promoting cell cycle progression in 
the G1 stage in dividing cells. Cyclin D1 forms molecular complexes with either cyclin-dependent kinase-4 
(CDK4) or CDK6. These complexes lead to phosphorylation of the retinoblastoma tumor suppressor protein 
(Rb), a nuclear protein. Phosphorylation of Rb results in the release of the transcription factor E2F, which 
commits the cell to proliferation. It has been found that inhibition of cyclin D1/CDK4 activity protects neurons 
from apoptosis, and up-regulation of cyclin D1 induces neuronal cell death [278-283]. Cultured neurons 
subjected to hypoxia showed an increase in the expression of cyclin D1. COX-2 inhibition with NS-398 
significantly reduced hypoxia-induced cyclin D1 protein expression. These findings were also replicated in the 
in vivo situation, where SC-58125, a highly selective COX-2 inhibitor, significantly attenuated the increase in 
cyclin D1 expression after focal cerebral ischemia in rats [275]. In cortico-hippocampal primary neuronal 
cultures, the phosphorylation of Rb is induced in neurons overexpressing human COX-2 during response to 
glutamate-mediated excitotoxic apoptotic damage [276;284]. Together, these results indicate that COX-2 
activity may induce neuronal cell death following ischemia by inducing the expression of cyclin D1 and 
unsuccessful entry into the cell cycle.   
 
The active principles of Cannabis sativa L, known popularly as marijuana, are a group of terpenophenolic 
compounds termed cannabinoids, which bind to the receptors CB1 and CB2. The endogenous ligands for 
these receptors are called endocannabinoids, and are physiologically produced by several cell types in the 
body. Relative recent investigations have shown that COX-2, but not COX-1, is able to oxygenate the 
endocannabinoids 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide or AEA) to 
yield new types of prostaglandins: prostaglandin glyceryl esters and prostaglandin ethanolamides 
[64;65;285;286]. The endocannabinoid signaling through CB1 and/or CB2 receptors has been reported to 
confer protection against cerebral ischemia [287-292]. Thus, by decreasing the levels of endocannabinoids, 
increased COX-2 activity may block this endogenous protective response of the brain to ischemia. 
Furthermore, a very recent evidence indicates that PGE2 glyceryl ester, a major COX-2 oxidative metabolite of 
2-arachidonoyl glycerol, potentiated excitatory glutamatergic synaptic transmission and induced apoptotic cell 
death when added to primary hippocampal neurons [285]. However, it remains to be determined whether these 
mechanisms contribute to the neurotoxic effect of COX-2 in the scenario of brain ischemia/reperfusion. 
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CRITICAL APPRAISAL OF THE THERAPEUTIC POTENTIAL OF COX-2 INHIBITORS IN CEREBRAL 
ISCHEMIA 
 
As described earlier in this article, neuronal injury following ischemia is attenuated by COX-2 inhibitors in 
several animal models, indicating that these agents may be of therapeutic benefit in the management of 
patients with cerebral ischemia. Relevant from the therapeutic point of view, numerous investigations 
demonstrate neuroprotection even when the COX-2 inhibitor is administered in a delayed fashion. This is of 
great importance because most patients arrive in the emergency room several hours after the onset of 
ischemia, a time at which most available therapeutic options are no longer effective. In addition, 
neuroprotection exerted by COX-2 inhibitors is long-lasting and results in improvement of the neurological 
function.  
 
Despite all these promising lines of experimental evidences, clinical trials evaluating efficacy of COX-2 
inhibitors in patients with stroke are very unlikely. This is mainly due to recent concerns about the increased 
cardiovascular risk after chronic treatment with this class of pharmacological agents [74;293-298]. It has now 
been suggested that all COX inhibitors could potentially result in increased risk of cardiovascular events 
[295;299-301]. These drugs include the widely used ibuprofen, naproxen, diclofenac, celecoxib, among others. 
A recent clinical study indicates that COX-2 selective inhibitors may differ in their potential to cause harmful 
cerebrovascular effects. Use of rofecoxib and etoricoxib, but not of celecoxib was associated with an increased 
risk of ischemic stroke. Odds ratios of ischemic stroke appeared to increase with higher daily dose and longer 
duration of rofecoxib and etoricoxib use. Authors conclude that for the risk of ischemic stroke additional 
pharmacological properties of individual COX-2 inhibitors may be important [302]. It is noteworthy to mention 
that the increased toxicity of COX-2 inhibitors is observed after prolonged administration in patients at risk to 
develop cardiovascular events [303-306] and the relative cardiovascular risks of NSAIDs are similar in 
magnitude to other currently prescribed therapies [307]. 
 
Thus, the possible short-term benefits of COX-2 inhibition in patients with an acute ischemic stroke should not 
be overlooked. Based on the pre-clinical data, these agents could result in neuroprotection and significant 
improvement of the neurological function when given therapeutically for just few hours/days after ischemia in 
selected patients. As with any drug, the risk/benefit ratio should be always considered and carefully evaluated 
by the physician.  
 
Very little information is available on the long-term effects of COX inhibition in the ischemic brain. This is an 
important limitation of most of the experimental studies evaluating the efficacy of COX inhibitors in models of 
brain ischemia. Blockade of COX activity may alter the neurogenic response, and this could negatively impact 
the endogenous repairing mechanisms which follow cerebral ischemia. It has been demonstrated that repeated 
treatment with aspirin significantly reduced ischemia-induced proliferation of cells in the dentate gyrus of adult 
gerbils after global brain ischemia [308]. In a similar study, Sasaki and colleagues [309] found that both 
indomethacin and the COX-2 inhibitor NS-398 significantly blunted the enhancement of dentate gyrus 
proliferation of neural progenitor cells following ischemia in the mouse. Furthermore, in the post-ischemic 
dentate gyrus of heterozygous and homozygous COX-2 deficient mice, proliferating bromodeoxyuridine-
positive cells were significantly fewer than in wild-type littermates [309]. These results demonstrate that COX-2 
is an important modulator in enhancement of proliferation of neural progenitor cells after ischemia.  
 
Additionally, very recent pieces of evidence suggest that COX-2 plays an essential role in cerebral ischemic 
preconditioning, and could potentially have protective effects [310;311]. The beneficial roles of COX-2-derived 
metabolites in neurogenesis and ischemic tolerance should be carefully considered when developing 
neuroprotective strategies based on COX-2 inhibition or blockade of prostanoid receptors. 
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CONCLUSIONS AND FUTURE DIRECTIONS: TARGETS DOWNSTREAM OF COX INHIBITION 
 
Due to emerging evidence suggesting that inhibition of COX-2 may result in increased risk of cardiovascular 
events, efforts have been made to elucidate the downstream effectors of COX-2 neurotoxicity with the hope of 
developing new therapeutic agents lacking the detrimental side effects. Modulation of PGE2 effects through EP 
receptors appears to be a promising target.  
 
Pioneer work from the labs of Drs. Iadecola and Dore indicate that pharmacological blockade of the PGE2 
receptor EP1 using SC51089 or EP1 genetic deletion results in substantial neuroprotection against excitotoxic 
and ischemic cerebral damage [257;258;271]. Work by Kawano et al. [257] clearly showed that blockade of 
EP1 receptors reduced brain injury when administered 6 hours after MCAO, suggesting that EP1 receptor 
inhibition may be a viable therapeutic option in ischemic stroke [257].  It has also been demonstrated that 
agonists of EP2 or EP4 receptors exert neuroprotective effects in experimental models of excitotoxicity and 
cerebral ischemia [267-270].  
 
Although manipulation of PGE2 signaling using an agonist/antagonist approach seems to be a valid therapeutic 
strategy, none of these pharmacological agents are clinically available, and thorough pharmacodynamic and 
toxicological studies remain to be performed before patients suffering from stroke will benefit from the 
therapeutic use of these compounds.  
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Fig. 1. Arachidonic acid metabolism through COX-1 or COX-2 results in the 
production of different prostanoids, which exert their biological effects via specific 
receptors, coupled to various signaling transduction pathways. It should be noted 
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Fig. 2. Proposed mechanisms associated with the neurotoxicity of increased 
COX-2 activity following brain ischemia. 
